Clinical Biochemistry of Diabetes: Advances in Biomarkers for Early Diagnosis and Management

Weise Le

doi:10 .4172/2327-4581.1000411

Short Communication, J Biochem Physiol Vol: 7 Issue: 2

Clinical Biochemistry of Diabetes: Advances in Biomarkers for Early Diagnosis and Management

Weise Le^*

¹Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, USA

*Corresponding Author: Weise Le,
Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, USA
E-mail: lisu@n.cn

Received date: 28 May, 2024, Manuscript No. JBPY-24-139483

Editor assigned date: 30 May, 2024, PreQC No. JBPY-24-139483 (PQ);

Reviewed date: 13 June, 2024, QC No. JBPY-24-139483

Revised date: 21 June, 2024, Manuscript No. JBPY-24-139483 (R);

Published date: 28 June, 2024, DOI: 10.4172/jbpy.1000164.

Citation: Thazhe A (2024) Clinical Biochemistry of Diabetes: Advances in Biomarkers for Early Diagnosis and Management. J Biochem Physiol 7:2.

Download PDF

Description

Diabetes Mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia due to insulin deficiency or resistance. The global burden of diabetes is substantial, with significant implications for morbidity, mortality, and healthcare costs. Advances in clinical biochemistry have led to the identification of novel biomarkers that improve the early diagnosis and management of diabetes, offering hope for better disease outcomes and reduced complications.

Traditional biomarkers in diabetes

Historically, the diagnosis and management of diabetes have relied on biomarkers such as Fasting Plasma Glucose (FPG), Oral Glucose Tolerance Test (OGTT), and glycated hemoglobin (HbA1c). These markers measure glucose levels directly or assess long-term glycemic control. FPG and OGTT are used to diagnose diabetes, whereas HbA1c provides an estimate of average blood glucose over the past two to three months [1]. Despite their widespread use, these markers have limitations, including variability in glucose levels due to diet, stress, and measurement conditions, and their inability to detect prediabetes reliably [2]. Glycated Albumin (GA) reflects intermediateterm glycemic control, providing an average glucose level over the previous two to four weeks. It is particularly useful in situations where HbA1c may be misleading, such as in patients with hemoglobinopathies or conditions affecting red blood cell turnover. Studies have shown that GA is a better predictor of diabetic complications and can complement HbA1c in clinical practice [3].

1,5-Anhydroglucitol (1,5-AG) is a monosaccharide whose levels inversely correlate with glucose spikes in the blood. It provides information about short-term glycemic control, capturing fluctuations that HbA1c might miss. Low levels of 1,5-AG indicate frequent postprandial hyperglycemia, making it a useful tool for identifying patients at risk for diabetes complications due to glucose variability [4]. Adiponectin, an adipose tissue-derived hormone, plays a crucial role in glucose regulation and fatty acid oxidation. Low levels of adiponectin are associated with insulin resistance and type 2 diabetes. Measuring adiponectin can help identify individuals at high risk for developing diabetes and can be a target for therapeutic interventions aimed at improving insulin sensitivity.Applications in Pharmaceutical Synthesis.

C-peptide, a byproduct of insulin production, provides a measure of endogenous insulin secretion. It is useful in distinguishing between type 1 and type 2 diabetes and can help in evaluating beta-cell function. Higher C-peptide levels in type 2 diabetes indicate preserved beta-cell function and can guide treatment decisions [5]. MicroRNAs (miRNAs) are small non-coding RNAs involved in gene regulation. Specific miRNAs are altered in diabetes and can serve as biomarkers for early diagnosis and monitoring of disease progression. miRNA profiles can provide insights into the molecular mechanisms of diabetes and offer new avenues for targeted therapies [6]. Proinsulin, the precursor of insulin, is elevated in insulin resistance and type 2 diabetes. Measuring proinsulin can provide insights into beta-cell dysfunction and the early stages of diabetes. It helps in understanding the pathophysiology of diabetes and can serve as a marker for disease progression [7].

Emerging biomarkers, such as GA and 1,5-AG, allow for the detection of glucose dysregulation before the development of overt diabetes. This early detection facilitates timely interventions, potentially delaying or preventing the onset of diabetes [8]. Biomarkers like adiponectin and miRNAs can provide personalized insights into an individual’s risk profile and response to treatment. This enables healthcare providers to tailor interventions based on the patient’s unique biochemical makeup, improving outcomes [9]. Markers such as GA and C-peptide provide additional information on glycemic control and beta-cell function, complementing traditional measures like HbA1c. This comprehensive approach enhances the monitoring of diabetes and helps in adjusting treatment regimens more effectively [10].

Conclusion

Advances in biomarkers for diabetes have the potential to revolutionize the early diagnosis and management of this chronic disease. Emerging biomarkers such as glycated albumin, 1,5- anhydroglucitol, adiponectin, C-peptide, microRNAs, and proinsulin provide valuable insights into glycemic control, beta-cell function, and disease progression. Their integration into clinical practice can lead to more timely and personalized interventions, improving patient outcomes and reducing the burden of diabetes. As research continues to advance, the clinical utility of these biomarkers is likely to expand, offering new hope for better management of diabetes.